OPALIN

OPALIN (TMEM10) is a CNS-specific type I transmembrane sialylglycoprotein selectively expressed by oligodendrocytes and concentrated at paranodal loop membranes, where it acts in oligodendrocyte differentiation and myelination (PMID:18571792, PMID:18490449). It has a short N-terminal extracellular domain bearing N-glycans at Asn-6/Asn-12 and a sialylated O-glycan at Thr-14, and these glycosylation sites are required for proper cell-surface localization (PMID:18490449). OPALIN functions as an oligodendrocyte-membrane receptor for the secreted protein LGI1; this interaction, mediated by extracellular residues K23/D26, sustains the transcription factors Sox10 and Olig2, and conditional deletion of OPALIN causes hypomyelination and white matter abnormalities that phenocopy LGI1 deficiency, with viral re-expression of wild-type but not the LGI1-binding-deficient K23A/D26A mutant rescuing the defect (PMID:39083419). Consistent with this role, OPALIN promotes oligodendrocyte terminal differentiation, process extension and branching, and induction of myelin-associated genes in gain- and loss-of-function assays (PMID:30837646). Its abundance is controlled post-translationally through a lysosomal degradation pathway that is accelerated by 2-hydroxylated sphingolipids (PMID:33215680), and its transcription is driven by a first-intron oligodendrocyte enhancer responsive to Myt1, LIF, and cAMP/CREB signaling (PMID:17442045). Conventional OPALIN knockout mice nonetheless show grossly normal CNS myelin architecture with only a subtle reduction in exploratory behavior, indicating it is not strictly required for basic myelin assembly under standard conditions (PMID:27855200).

1. 2007 High

   Before any transcriptional control was known, it was unclear how Opalin achieves oligodendrocyte-restricted expression; identifying a lineage-directed enhancer and its trans-factors established the regulatory logic of its expression.

   Evidence Transgenic mouse enhancer assay and reporter cotransfection in Oli-neu cells with deletion analysis and Myt1 overexpression/LIF/cAMP stimulation

   PMID:17442045

   Open questions at the time

   • Does not link enhancer activity to a downstream functional output of OPALIN
   • Direct binding of Myt1 and CREB to the enhancer not biochemically resolved beyond site presence
2. 2008 Medium

   The cellular and subcellular distribution of OPALIN was undefined; demonstrating CNS-restricted oligodendrocyte expression with paranodal concentration and absence from Schwann cells positioned it as a candidate CNS myelin component.

   Evidence In situ hybridization, RT-PCR, developmental immunofluorescence, and myelinating spinal cord cultures

   PMID:18571792

   Open questions at the time

   • Localization alone does not establish a molecular function
   • No binding partner or pathway identified
3. 2008 High

   The topology and post-translational modification of OPALIN were unknown; defining it as a type I transmembrane sialylglycoprotein and showing that defined N-/O-glycosylation sites are required for surface delivery established the structural basis of its membrane presentation.

   Evidence Biochemical characterization, enzymatic deglycosylation, site-directed mutagenesis with surface-localization readout, and immunogold electron microscopy

   PMID:18490449

   Open questions at the time

   • The functional role of the cytoplasmic C-terminal domain not addressed
   • Did not connect glycosylation to a signaling or differentiation function
4. 2014 Low

   Whether OPALIN modification changes over development was unexamined; documenting age-dependent O-glycan hypersialylation and regional redistribution suggested its glycoform is dynamically regulated with maturation.

   Evidence Western blot with enzymatic deglycosylation and immunofluorescence across postnatal time points in mouse brain

   PMID:25153515

   Open questions at the time

   • Descriptive only with limited functional follow-up
   • Single lab; functional consequence of hypersialylation not established
5. 2016 Medium

   It was unknown whether OPALIN is essential for myelination; a complete knockout showing grossly normal myelin but reduced exploratory behavior established that it is dispensable for basic myelin assembly while hinting at a non-structural role.

   Evidence Opalin knockout mice analyzed by electron microscopy, Western blot, immunofluorescence, and behavioral testing

   PMID:27855200

   Open questions at the time

   • Negative myelin phenotype may reflect compensation or non-stressed conditions
   • Mechanistic basis of the behavioral phenotype not determined
6. 2019 Medium

   The cell-autonomous contribution of OPALIN to oligodendrocyte maturation was unclear; reciprocal gain- and loss-of-function showed it promotes terminal differentiation, morphology, and myelin gene expression, establishing a pro-differentiation role.

   Evidence Overexpression in Oli-neu cells and siRNA knockdown in primary OPCs with qRT-PCR and immunofluorescence

   PMID:30837646

   Open questions at the time

   • Mechanism downstream of OPALIN not defined at this stage
   • In vitro systems; relationship to in vivo dispensability in knockout unresolved
7. 2024 High

   OPALIN lacked a defined molecular partner and signaling mechanism; identifying it as the oligodendrocyte receptor for LGI1 and showing K23/D26-dependent rescue of hypomyelination established a ligand-receptor axis sustaining Sox10/Olig2 expression.

   Evidence LGI1-FLAG affinity chromatography plus mass spectrometry, conditional knockout mice, Sox10/Olig2 analysis, and viral rescue with wild-type versus K23A/D26A binding-deficient OPALIN

   PMID:39083419

   Open questions at the time

   • Intracellular signal transduction linking LGI1-OPALIN binding to Sox10/Olig2 not delineated
   • Reconciliation with the mild conventional knockout phenotype not fully resolved

• How LGI1-OPALIN binding is transduced through the cytoplasmic domain to regulate Sox10/Olig2 transcription, and how glycosylation/lysosomal turnover tunes receptor availability, remain unresolved.
• No downstream signaling effector of OPALIN identified
• Link between glycoform/lysosomal turnover and LGI1 receptor function untested
• No structural model of the LGI1-OPALIN interface